Document Detail


Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy.
MedLine Citation:
PMID:  2040038     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The addition of high-dose methylprednisolone (120 mg given i.v. and repeated after a 4-h interval) to a conventional antiemetic regimen consisting of metoclopramide (0.5 mg/kg given as an i.v. bolus over 30 min followed by 1 mg/kg given as a continuous infusion over 24 h) and alprazolam (0.5 mg given p.o.) was evaluated in a randomized study of leukemic patients undergoing anthracycline-containing multiple-day chemotherapy. Double-blind analysis was done in 30 patients who completed a total of 40 treatment courses. Cumulative 3-day results revealed complete control of nausea in 66% of patients and complete control of emesis in 77% of cases. The addition of methylprednisolone significantly reduced the occurrence of nausea (p = 0.003) and emesis (P = 0.06). Moreover, antiemetic rescue with chlorpromazine was less frequently necessary in patients receiving corticosteroids (P = 0.02). No harmful side effect was observed, and the incidence of severe infectious episodes was similar in both arms. We conclude that high-dose methylprednisolone can improve the efficacy of metoclopramide and alprazolam in controlling nausea and emesis induced by anthracycline-containing multiple-day chemotherapy in patients with acute myeloblastic leukemia.
Authors:
G Salles; E Archimbaud; X Thomas; D Fiere
Related Documents :
1280628 - Enhancement of host defense by y-25510, (+-)-3-[4-(2-dimethylamino-1-methylethoxy)pheny...
8952558 - High dose etoposide-based myeloablative therapy followed by autologous blood progenitor...
2651578 - Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodys...
12818978 - A comparison of dexamethasone, ondansetron, and dexamethasone plus ondansetron as proph...
19450908 - Long-term investigation of anthropogenic and naturally occurring radionuclides at refer...
21402128 - Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pa...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  28     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1991-07-09     Completed Date:  1991-07-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  77-9     Citation Subset:  IM    
Affiliation:
Service d'Hématologie, Hôpital E. Herriot, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Alprazolam / administration & dosage*,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*
Double-Blind Method
Drug Therapy, Combination
Humans
Leukemia, Myeloid, Acute / complications,  drug therapy
Methylprednisolone / administration & dosage*,  adverse effects
Metoclopramide / administration & dosage*,  adverse effects
Middle Aged
Nausea / chemically induced,  prevention & control
Time Factors
Vomiting / chemically induced,  prevention & control*
Chemical
Reg. No./Substance:
28981-97-7/Alprazolam; 364-62-5/Metoclopramide; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and...
Next Document:  Selective gene expression in failing human heart. Quantification of steady-state levels of messenger...